The purpose of this study is to see the effect of adding a systemic study drug, Ipilimumab,
to two standard chemotherapy drugs, Melphalan and Dactinomycin. The study drug Ipilimumab is
an antibody to a normal protein found in the body, CTLA-4. This protein normally allows the
immune system (the body's natural defense system that helps fight infections) uses to quiet
an immune response. The study drug works by blocking this protein and allowing the immune
system to become more active. This study will investigate the effects, of combining ILI
(using two standard drugs to treat melanoma, Melphalan and Dactinomycin), with the study
drug, Ipilimumab on advanced Melanoma cancer.